Why Medical Properties Trust Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 15 2024
0mins
Source: Benzinga
- Medical Properties Trust, Inc. Announcement: Medical Properties Trust, Inc. saw a rise in shares after selling its majority interest in Utah Hospitals.
- Stock Market Gainers: Various stocks experienced gains in pre-market trading, including Allarity Therapeutics, Longeveron Inc., SuperCom Ltd., and others.
- Stock Market Losers: Some stocks faced declines in pre-market trading, such as AudioEye, NextPlat Corp, Organovo Holdings Inc, and more.
- Goldman Sachs Earnings Forecast: Goldman Sachs is expected to report lower Q1 earnings, with forecast changes from Wall Street analysts.
Analyst Views on LGVN
Wall Street analysts forecast LGVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LGVN is 3.50 USD with a low forecast of 3.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.564
Low
3.00
Averages
3.50
High
4.00
Current: 0.564
Low
3.00
Averages
3.50
High
4.00
About LGVN
Longeveron Inc. is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The Company is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
